Celldex Therapeutics
CLDX
131 hedge funds and large institutions have $1.17B invested in Celldex Therapeutics in 2021 Q2 according to their latest regulatory filings, with 40 funds opening new positions, 33 increasing their positions, 36 reducing their positions, and 24 closing their positions.
67% more first-time investments, than exits
New positions opened: 40 | Existing positions closed: 24
65% more capital invested
Capital invested by funds: $710M → $1.17B (+$464M)
25% more funds holding in top 10
Funds holding in top 10: 4 → 5 (+1)
14% more funds holding
Funds holding: 115 → 131 (+16)
1.83% more ownership
Funds ownership: 87.2% → 89.03% (+1.8%)
8% less repeat investments, than reductions
Existing positions increased: 33 | Existing positions reduced: 36
15% less call options, than puts
Call options by funds: $33.4M | Put options by funds: $39.5M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
+$47.6M |
| 2 |
PA
Perceptive Advisors
New York
|
+$20.4M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$8.79M |
| 4 |
Northern Trust
Chicago,
Illinois
|
+$8.37M |
| 5 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$6.49M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$16.6M |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$14.4M |
| 3 |
Millennium Management
New York
|
-$10.4M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
-$10.3M |
| 5 |
TCMG
TSP Capital Management Group
Summit,
New Jersey
|
-$9.86M |
CLDX Hedge Fund Activity: Q2 2021 in Review
131 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Celldex Therapeutics (CLDX) for Q2 2021, worth a combined $1.17B — up 65% from $710M a quarter earlier.
Buyers outnumbered sellers: 40 funds opened new CLDX positions and 24 closed out — a net gain of 16 holders — while 33 added to existing stakes and 36 trimmed.
The largest buyer was BlackRock, adding an estimated $47.6M. The largest seller was Citadel Advisors, cutting an estimated $16.6M.
- 131 institutional investors held Celldex Therapeutics (CLDX) as of Q2 2021, up from 115 in Q1 2021.
- Funds reported $1.17B of Celldex Therapeutics stock for Q2 2021, up 65% quarter-over-quarter.
- 40 funds opened new Celldex Therapeutics positions in Q2 2021 and 24 closed out, a net change of +16 holders.
- The largest Celldex Therapeutics buyer in Q2 2021 was BlackRock, an estimated $47.6M added.
- The largest Celldex Therapeutics seller in Q2 2021 was Citadel Advisors, an estimated $16.6M sold.
Based on aggregated 13F filings for Q2 2021.